Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 2.63 is 16% above its 5-year average of 2.27, around the middle of its 5-year range (0.60–6.20).
As of the fiscal period ended Tuesday, June 30, 2026. 14.18% below its 12-month average of 3.07.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.63.
DEBT TO EQUITY RATIO
2.63
DEBT TO EQUITY RATIO AVG TTM
3.07
DEBT TO EQUITY RATIO AVG 3Y
2.33
DEBT TO EQUITY RATIO AVG 5Y
2.27
DEBT TO EQUITY RATIO AVG 10Y
1.50
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-14.18%
CURRENT VS 3Y AVG
+13.04%
CURRENT VS 5Y AVG
+15.81%
CURRENT VS 10Y AVG
+75.19%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+2292.20%
vs the sector median at left
Axsome Therapeutics, Inc.
Market Cap
$9.04B
Debt to Equity Ratio
2.63
TTM Avg
3.07
3Y Avg
2.33
5Y Avg
2.27
Market Cap
$8.98B
Debt to Equity Ratio
0.80
TTM Avg
1.04
3Y Avg
1.06
5Y Avg
1.08
Market Cap
$9.25B
Debt to Equity Ratio
0.80
TTM Avg
1.04
3Y Avg
1.06
5Y Avg
1.08
Market Cap
$8.90B
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$8.79B
Debt to Equity Ratio
1.86
TTM Avg
2.69
3Y Avg
1.75
5Y Avg
1.18
Market Cap
$8.64B
Debt to Equity Ratio
0.05
TTM Avg
0.08
3Y Avg
0.10
5Y Avg
0.09
Market Cap
$9.61B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $9.04B | 2.63 | 3.07 | 2.33 | 2.27 |
| Bruker Corporation (BRKRP)vs › | $8.98B | 0.80 | 1.04 | 1.06 | 1.08 |
| Bruker Corporation (BRKR)vs › | $9.25B | 0.80 | 1.04 | 1.06 | 1.08 |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.90B | 0.01 | 0.02 | 0.01 | 0.02 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.79B | 1.86 | 2.69 | 1.75 | 1.18 |
| Insulet Corp. (PODD)vs › | $9.38B | 0.67 | 0.93 | 1.71 | 1.82 |
| Vaxcyte, Inc. (PCVX)vs › | $9.47B | 0.04 | 0.06 | 0.04 | 0.04 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.64B | 0.05 | 0.08 | 0.10 | 0.09 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.61B | 0.01 | 0.01 | 0.01 | 0.02 |
| Henry Schein, Inc. (HSIC)vs › | $9.65B | 1.21 | 0.99 | 0.79 | 0.64 |
Debt/Equity
2.63
Current Ratio
1.43
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 2.63 |
| 2026-03-31 | 4.03 |
| 2025-12-31 | 2.73 |
| 2025-09-30 | 2.96 |
| 2025-06-30 | 2.97 |
| 2025-03-31 | 3.97 |
| 2024-12-31 | 3.38 |
| 2024-09-30 | 2.07 |
| 2024-06-30 | 1.86 |
| 2024-03-31 | 1.32 |
| 2023-12-31 | 0.98 |
| 2023-09-30 | 0.69 |
| 2023-06-30 | 0.66 |
| 2023-03-31 | 1.32 |
| 2022-12-31 | 0.86 |
| 2022-09-30 | 0.60 |
| 2022-06-30 | 6.20 |
| 2022-03-31 | 3.42 |
| 2021-12-31 | 3.18 |
| 2021-09-30 | 1.17 |
| 2021-06-30 | 0.70 |
| 2021-03-31 | 0.52 |
| 2020-12-31 | 0.44 |
| 2020-09-30 | 0.36 |
| 2020-06-30 | 0.13 |
| 2020-03-31 | 0.13 |
| 2019-12-31 | 0.11 |
| 2019-09-30 | 2.90 |
| 2019-06-30 | 0.81 |
| 2019-03-31 | 1.11 |
| 2018-12-31 | 7.37 |
| 2018-09-30 | 10.40 |
| 2018-06-30 | 1.21 |
| 2018-03-31 | 0.73 |
| 2017-12-31 | 0.59 |
| 2017-09-30 | 0.60 |
| 2017-06-30 | 0.44 |
| 2017-03-31 | 0.34 |
| 2016-12-31 | 0.45 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 3.88 |
| 2015-06-30 | -1.51 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | -1.40 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
